{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T14:03:23Z","timestamp":1774620203622,"version":"3.50.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Philadelphia (Ph)-negative myeloproliferative neoplasms (MPNs), namely essential thrombocythaemia (ET), polycythaemia vera (PV) and primary myelofibrosis (PMF), are a group of chronic clonal haematopoietic disorders that have the propensity to advance into bone marrow failure or acute myeloid leukaemia; often resulting in fatality. Although driver mutations have been identified in these MPNs, subtype-specific markers of the disease have yet to be discovered. Next-generation sequencing (NGS) technology can potentially improve the clinical management of MPNs by allowing for the simultaneous screening of many disease-associated genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The performance of a custom, in-house designed 22-gene NGS panel was technically validated using reference standards across two independent replicate runs. The panel was subsequently used to screen a total of 10 clinical MPN samples (ET n\u2009=\u20093, PV n\u2009=\u20093, PMF n\u2009=\u20094). The resulting NGS data was then analysed via a bioinformatics pipeline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The custom NGS panel had a detection limit of 1% variant allele frequency (VAF). A total of 20 unique variants with VAFs above 5% (4 of which were putatively novel variants with potential biological significance) and one pathogenic variant with a VAF of between 1 and 5% were identified across all of the clinical MPN samples. All single nucleotide variants with VAFs\u2009\u2265\u200915% were confirmed via Sanger sequencing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The high fidelity of the NGS analysis and the identification of known and novel variants in this study cohort support its potential clinical utility in the management of MPNs. However, further optimisation is needed to avoid false negatives in regions with low sequencing coverage, especially for the detection of driver mutations in\n                      <jats:italic>MPL<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-021-01145-0","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T02:03:09Z","timestamp":1642212189000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel"],"prefix":"10.1186","volume":"15","author":[{"given":"Jaymi","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yock Ping","family":"Chow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norziha","family":"Zainul Abidin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kian Meng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veena","family":"Selvaratnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nor Rafeah","family":"Tumian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang Ming","family":"Poh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhi","family":"Veerakumarasivam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Arthur","family":"Laffan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh Lee","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"issue":"5","key":"1145_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905\u201314.","journal-title":"Leukemia"},{"issue":"Suppl 5","key":"1145_CR2","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(Suppl 5):v85\u201399.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"18","key":"1145_CR3","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","volume":"121","author":"A Mullally","year":"2013","unstructured":"Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera. Blood. 2013;121(18):3692\u2013702.","journal-title":"Blood"},{"key":"1145_CR4","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2017","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe E, Pileri S, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer (IARC) Press; 2017.","edition":"4"},{"issue":"20","key":"1145_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"3","key":"1145_CR6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3324\/haematol.2011.047811","volume":"97","author":"T Buhr","year":"2012","unstructured":"Buhr T, Hebeda K, Kaloutsi V, Porwit A, Van der Walt J, Kreipe H. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360\u20135.","journal-title":"Haematologica"},{"issue":"1","key":"1145_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","volume":"111","author":"BS Wilkins","year":"2008","unstructured":"Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood. 2008;111(1):60\u201370.","journal-title":"Blood"},{"issue":"6","key":"1145_CR8","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1365-2559.2010.03545.x","volume":"56","author":"M Brousseau","year":"2010","unstructured":"Brousseau M, Parot-Schinkel E, Moles MP, Boyer F, Hunault M, Rousselet MC. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology. 2010;56(6):758\u201367.","journal-title":"Histopathology"},{"issue":"15","key":"1145_CR9","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416\u201330.","journal-title":"N Engl J Med"},{"issue":"21","key":"1145_CR10","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1093\/bioinformatics\/btp394","volume":"25","author":"K Ye","year":"2009","unstructured":"Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009;25(21):2865\u201371.","journal-title":"Bioinformatics"},{"issue":"2","key":"1145_CR11","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/jcmm.13979","volume":"23","author":"Y Dai","year":"2019","unstructured":"Dai Y, Liang S, Dong X, Zhao Y, Ren H, Guan Y, et al. Whole exome sequencing identified a novel DAG1 mutation in a patient with rare, mild and late age of onset muscular dystrophy-dystroglycanopathy. J Cell Mol Med. 2019;23(2):811\u20138.","journal-title":"J Cell Mol Med"},{"key":"1145_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fgene.2018.00129","volume":"9","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Xu J, Liang S, Lin D, Banerjee S. Whole exome sequencing identified a novel heterozygous mutation in HMBS gene in a Chinese patient with acute intermittent porphyria with rare type of mild anemia. Front Genet. 2018;9:129.","journal-title":"Front Genet"},{"issue":"1","key":"1145_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/nar\/29.1.308","volume":"29","author":"ST Sherry","year":"2001","unstructured":"Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308\u201311.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"1145_CR14","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42(Database issue):D980\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"1145_CR15","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2018","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2018;47(D1):D941\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"1145_CR16","first-page":"D682","volume":"48","author":"AD Yates","year":"2019","unstructured":"Yates AD, Achuthan P, Akanni W, Allen J, Allen J, Alvarez-Jarreta J, et al. Ensembl 2020. Nucleic Acids Res. 2019;48(D1):D682\u20138.","journal-title":"Nucleic Acids Res"},{"key":"1145_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2105-13-134","volume":"13","author":"J Ye","year":"2012","unstructured":"Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction. BMC Bioinform. 2012;13:134.","journal-title":"BMC Bioinform"},{"issue":"9","key":"1145_CR18","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/bioinformatics\/btp033","volume":"25","author":"AM Waterhouse","year":"2009","unstructured":"Waterhouse AM, Procter JB, Martin DMA, Clamp M, Barton GJ. Jalview Version 2\u2014a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009;25(9):1189\u201391.","journal-title":"Bioinformatics"},{"issue":"9","key":"1145_CR19","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/leu.2010.144","volume":"24","author":"O Abdel-Wahab","year":"2010","unstructured":"Abdel-Wahab O, Kilpivaara O, Patel J, Busque L, Levine RL. The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration. Leukemia. 2010;24(9):1656\u20137.","journal-title":"Leukemia"},{"issue":"25","key":"1145_CR20","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391\u2013405.","journal-title":"N Engl J Med"},{"issue":"22","key":"1145_CR21","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616\u201327.","journal-title":"Blood"},{"issue":"5","key":"1145_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/leu.2011.10","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Kohlmann A, Eder C, Haferlach C, Kern W, Cross NC, et al. Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia. 2011;25(5):877\u20139.","journal-title":"Leukemia"},{"issue":"3","key":"1145_CR23","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3324\/haematol.2011.051532","volume":"97","author":"M Pratcorona","year":"2012","unstructured":"Pratcorona M, Abbas S, Sanders MA, Koenders JE, Kavelaars FG, Erpelinck-Verschueren CA, et al. Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica. 2012;97(3):388\u201392.","journal-title":"Haematologica"},{"issue":"8","key":"1145_CR24","doi-asserted-by":"publisher","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","volume":"7","author":"F Traina","year":"2012","unstructured":"Traina F, Visconte V, Jankowska AM, Makishima H, O\u2019Keefe CL, Elson P, et al. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS ONE. 2012;7(8):e43090.","journal-title":"PLoS ONE"},{"issue":"12","key":"1145_CR25","first-page":"1069","volume":"35","author":"Y Cui","year":"2014","unstructured":"Cui Y, Li B, Jiang Q, Xu Z, Qin T, Zhang P, et al. CSF3R, ASXL1, SETBP1, JAK2 V617F and CALR mutations in chronic neutrophilic leukemia. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2014;35(12):1069\u201373.","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"issue":"17","key":"1145_CR26","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/cncr.30102","volume":"122","author":"JS Ross","year":"2016","unstructured":"Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: an emerging opportunity for anti-HER2 targeted therapies. Cancer. 2016;122(17):2654\u201362.","journal-title":"Cancer"},{"issue":"10","key":"1145_CR27","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/ng.3382","volume":"47","author":"AH Shain","year":"2015","unstructured":"Shain AH, Garrido M, Botton T, Talevich E, Yeh I, Sanborn JZ, et al. Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. Nat Genet. 2015;47(10):1194\u20139.","journal-title":"Nat Genet"},{"key":"1145_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41523-018-0070-x","volume":"4","author":"YS Yap","year":"2018","unstructured":"Yap YS, Singh AP, Lim JHC, Ahn JH, Jung KH, Kim J, et al. Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. NPJ Breast Cancer. 2018;4:19.","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"1145_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3960\/jslrt.55.145","volume":"55","author":"K Shimoda","year":"2015","unstructured":"Shimoda K, Shide K, Kameda T, Hidaka T, Kubuki Y, Kamiunten A, et al. TET2 mutation in adult T-Cell leukemia\/lymphoma. J Clin Exp Hematopathol. 2015;55(3):145\u20139.","journal-title":"J Clin Exp Hematopathol"},{"issue":"3","key":"1145_CR30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.leukres.2012.10.004","volume":"37","author":"J Wang","year":"2013","unstructured":"Wang J, Ai X, Gale RP, Xu Z, Qin T, Fang L, et al. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res. 2013;37(3):305\u201311.","journal-title":"Leuk Res"},{"issue":"10","key":"1145_CR31","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1200\/JCO.2010.32.7742","volume":"29","author":"KH Metzeler","year":"2011","unstructured":"Metzeler KH, Maharry K, Radmacher MD, Mr\u00f3zek K, Margeson D, Becker H, et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Oncol Off J Am Soc Clin Oncol. 2011;29(10):1373\u201381.","journal-title":"J Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"1145_CR32","first-page":"173","volume":"44","author":"JS Ha","year":"2014","unstructured":"Ha JS, Jeon DS, Kim JR, Ryoo NH, Suh JS. Analysis of the ten-eleven translocation 2 (TET2) gene mutation in myeloproliferative neoplasms. Ann Clin Lab Sci. 2014;44(2):173\u20139.","journal-title":"Ann Clin Lab Sci"},{"issue":"9","key":"1145_CR33","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123(9):1293\u20136.","journal-title":"Blood"},{"issue":"10","key":"1145_CR34","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/leu.2011.139","volume":"25","author":"C Roche-Lestienne","year":"2011","unstructured":"Roche-Lestienne C, Marceau A, Labis E, Nibourel O, Coiteux V, Guilhot J, et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia. 2011;25(10):1661\u20134.","journal-title":"Leukemia"},{"issue":"1","key":"1145_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/ng.1031","volume":"44","author":"TA Graubert","year":"2011","unstructured":"Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011;44(1):53\u20137.","journal-title":"Nat Genet"},{"issue":"7367","key":"1145_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/nature10496","volume":"478","author":"K Yoshida","year":"2011","unstructured":"Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64\u20139.","journal-title":"Nature"},{"issue":"15","key":"1145_CR37","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","volume":"365","author":"E Papaemmanuil","year":"2011","unstructured":"Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384\u201395.","journal-title":"N Engl J Med"},{"issue":"2","key":"1145_CR38","doi-asserted-by":"publisher","first-page":"R18","DOI":"10.1186\/gb-2011-12-2-r18","volume":"12","author":"D Aird","year":"2011","unstructured":"Aird D, Ross MG, Chen W-S, Danielsson M, Fennell T, Russ C, et al. Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries. Genome Biol. 2011;12(2):R18.","journal-title":"Genome Biol"},{"issue":"10","key":"1145_CR39","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1093\/nar\/gks001","volume":"40","author":"Y Benjamini","year":"2012","unstructured":"Benjamini Y, Speed TP. Summarizing and correcting the GC content bias in high-throughput sequencing. Nucleic Acids Res. 2012;40(10):e72.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1145_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/jcm9010132","volume":"9","author":"R Pereira","year":"2020","unstructured":"Pereira R, Oliveira J, Sousa M. Bioinformatics and computational tools for next-generation sequencing analysis in clinical genetics. J Clin Med. 2020;9(1):132.","journal-title":"J Clin Med"},{"issue":"2","key":"1145_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/leu.2013.336","volume":"28","author":"T Haferlach","year":"2014","unstructured":"Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2):241\u20137.","journal-title":"Leukemia"},{"issue":"15","key":"1145_CR42","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1182\/blood-2011-12-399337","volume":"119","author":"F Thol","year":"2012","unstructured":"Thol F, Kade S, Schlarmann C, L\u00f6ffeld P, Morgan M, Krauter J, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood. 2012;119(15):3578\u201384.","journal-title":"Blood"},{"issue":"6","key":"1145_CR43","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1056\/NEJMoa1611604","volume":"376","author":"RC Lindsley","year":"2017","unstructured":"Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536\u201347.","journal-title":"N Engl J Med"},{"issue":"8","key":"1145_CR44","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/s41375-018-0193-y","volume":"32","author":"MO Alberti","year":"2018","unstructured":"Alberti MO, Srivatsan SN, Shao J, McNulty SN, Chang GS, Miller CA, et al. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. Leukemia. 2018;32(8):1874\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"1145_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3324\/haematol.2014.113845","volume":"102","author":"J Grinfeld","year":"2017","unstructured":"Grinfeld J, Nangalia J, Green AR. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica. 2017;102(1):7\u201317.","journal-title":"Haematologica"},{"issue":"23","key":"1145_CR46","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"1145_CR47","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1038\/s41598-019-38672-x","volume":"9","author":"C Chandrasekhar","year":"2019","unstructured":"Chandrasekhar C, Kumar PS, Sarma PVGK. Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients. Sci Rep. 2019;9(1):2412.","journal-title":"Sci Rep"},{"issue":"6","key":"1145_CR48","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1634\/theoncologist.2010-0388","volume":"16","author":"S Soverini","year":"2011","unstructured":"Soverini S, Rosti G, Iacobucci I, Baccarani M, Martinelli G. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC50? Oncologist. 2011;16(6):868\u201376.","journal-title":"Oncologist"},{"issue":"7647","key":"1145_CR49","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature. 2017;543(7647):733\u20137.","journal-title":"Nature"},{"issue":"4","key":"1145_CR50","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1309\/AJCPPPZ1WFVGNE4A","volume":"133","author":"JM Klco","year":"2010","unstructured":"Klco JM, Vij R, Kreisel FH, Hassan A, Frater JL. Molecular pathology of myeloproliferative neoplasms. Am J Clin Pathol. 2010;133(4):602\u201315.","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"1145_CR51","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1412098","volume":"372","author":"CA Ortmann","year":"2015","unstructured":"Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601\u201312.","journal-title":"N Engl J Med"},{"issue":"11","key":"1145_CR52","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","volume":"100","author":"J Nangalia","year":"2015","unstructured":"Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J, Thakker C, et al. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica. 2015;100(11):e438\u201342.","journal-title":"Haematologica"},{"issue":"1","key":"1145_CR53","first-page":"170","volume":"17","author":"J Tan","year":"2021","unstructured":"Tan J, Chow YP, Abidin NZ, Veerakumarasivam A, Wong CL. From driver mutations to genomic classification: current & future perspectives on myeloproliferative neoplasms. Malays J Med Health Sci. 2021;17(1):170\u201383.","journal-title":"Malays J Med Health Sci"},{"issue":"1","key":"1145_CR54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/humu.23354","volume":"39","author":"G Robevska","year":"2018","unstructured":"Robevska G, van den Bergen JA, Ohnesorg T, Eggers S, Hanna C, Hersmus R, et al. Functional characterization of novel NR5A1 variants reveals multiple complex roles in disorders of sex development. Hum Mutat. 2018;39(1):124\u201339.","journal-title":"Hum Mutat"},{"key":"1145_CR55","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fgene.2019.00248","volume":"10","author":"G Wheway","year":"2019","unstructured":"Wheway G, Nazlamova L, Meshad N, Hunt S, Jackson N, Churchill A. A combined in silico, in vitro and clinical approach to characterize novel pathogenic missense variants in PRPF31 in retinitis pigmentosa. Front Genet. 2019;10:248.","journal-title":"Front Genet"},{"issue":"4","key":"1145_CR56","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1373\/clinchem.2015.249623","volume":"62","author":"TF Beck","year":"2016","unstructured":"Beck TF, Mullikin JC, Biesecker LG. Systematic evaluation of sanger validation of next-generation sequencing variants. Clin Chem. 2016;62(4):647\u201354.","journal-title":"Clin Chem"},{"issue":"1","key":"1145_CR57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ijlh.12425","volume":"38","author":"N Alghasham","year":"2016","unstructured":"Alghasham N, Alnouri Y, Abalkhail H, Khalil S. Detection of mutations in JAK2 exons 12\u201315 by Sanger sequencing. Int J Lab Hematol. 2016;38(1):34\u201341.","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"1145_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/humu.22685","volume":"36","author":"D Braunholz","year":"2015","unstructured":"Braunholz D, Obieglo C, Parenti I, Pozojevic J, Eckhold J, Reiz B, et al. Hidden mutations in Cornelia de Lange syndrome limitations of sanger sequencing in molecular diagnostics. Hum Mutat. 2015;36(1):26\u20139.","journal-title":"Hum Mutat"},{"key":"1145_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.exppara.2015.02.001","volume":"151\u2013152","author":"A Paparini","year":"2015","unstructured":"Paparini A, Gofton A, Yang R, White N, Bunce M, Ryan UM. Comparison of sanger and next generation sequencing performance for genotyping cryptosporidium isolates at the 18S rRNA and actin loci. Exp Parasitol. 2015;151\u2013152:21\u20137.","journal-title":"Exp Parasitol"},{"issue":"4","key":"1145_CR60","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2353\/jmoldx.2010.090188","volume":"12","author":"AC Tsiatis","year":"2010","unstructured":"Tsiatis AC, Norris-Kirby A, Rich RG, Hafez MJ, Gocke CD, Eshleman JR, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12(4):425\u201332.","journal-title":"J Mol Diagn"},{"issue":"4","key":"1145_CR61","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood-2017-03-734533","volume":"130","author":"FC Kuo","year":"2017","unstructured":"Kuo FC, Mar BG, Lindsley RC, Lindeman NI. The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood. 2017;130(4):433\u20139.","journal-title":"Blood"},{"issue":"11","key":"1145_CR62","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.3390\/ijms18112316","volume":"18","author":"M S\u0142omka","year":"2017","unstructured":"S\u0142omka M, Sobalska-Kwapis M, Wachulec M, Bartosz G, Strapagiel D. High resolution melting (HRM) for high-throughput genotyping-limitations and caveats in practical case studies. Int J Mol Sci. 2017;18(11):2316.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1145_CR63","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40246-017-0118-2","volume":"11","author":"JK Teer","year":"2017","unstructured":"Teer JK, Zhang Y, Chen L, Welsh EA, Cress WD, Eschrich SA, et al. Evaluating somatic tumor mutation detection without matched normal samples. Hum Genom. 2017;11(1):22.","journal-title":"Hum Genom"},{"issue":"8","key":"1145_CR64","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3324\/haematol.2019.218917","volume":"104","author":"C Baer","year":"2019","unstructured":"Baer C, Walter W, Hutter S, Twardziok S, Meggendorfer M, Kern W, et al. \u201cSomatic\u201d and \u201cpathogenic\u201d: is the classification strategy applicable in times of large-scale sequencing? Haematologica. 2019;104(8):1515\u201320.","journal-title":"Haematologica"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-021-01145-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T12:05:29Z","timestamp":1666613129000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-021-01145-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1186\/s12920-021-01145-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-721996\/v1","asserted-by":"object"}]},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"15 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance to the guidelines of the Declaration of Helsinki, and as approved by the Sunway Medical Centre Independent Research Ethics Committee (SREC 008\/2018\/FR, date of approval 27th June 2018), Universiti Kebangsaan Malaysia Medical Centre Research Ethics Committee (UKM FPR.4\/244\/FF-2018-420, date of approval 29th November 2018), Medical Research and Ethics Committee Ministry of Health Malaysia (MREC 8KKM\/NIHSEC\/P-19-99, date of approval 22nd January 2019), and Sunway University Research Ethics Committee (PGSUREC 2019\/010, date of approval 9th April 2019). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the funding institution and all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}